Abstract
Pancreatic cancer remains largely an incurable disease necessitating the development of novel therapeutic approaches. Adoptive immunotherapy using chimeric antigen receptor (CAR)-transduced T cells represents an alternative treatment with curative potential. We present an overview of the engineering of novel CARs targeting prostate stem cell antigen (PSCA), implications for the development of immunotherapies, and potential strategies to circumvent ontarget/ off-tumor toxicities.
Original language | English (US) |
---|---|
Article number | e29194 |
Journal | OncoImmunology |
Volume | 3 |
Issue number | 6 |
DOIs | |
State | Published - 2014 |
Keywords
- Adoptive immunotherapy
- Chimeric antigen receptors (CAR)
- PSCA
- Pancreatic cancer
- Synthetic biology
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology